HC Wainwright Issues Pessimistic Estimate for ENTA Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities researchers at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Tuesday, February 11th. HC Wainwright analyst E. Arce now anticipates that the biotechnology company will earn ($1.42) per share for the quarter, down from their prior forecast of ($1.32). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($5.05) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q3 2025 earnings at ($1.81) EPS, Q4 2025 earnings at ($2.00) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.50) EPS, FY2027 earnings at ($9.80) EPS, FY2028 earnings at ($9.50) EPS and FY2029 earnings at ($8.15) EPS.

ENTA has been the subject of several other research reports. Robert W. Baird lowered their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Enanta Pharmaceuticals Trading Up 4.8 %

Shares of NASDAQ:ENTA opened at $5.86 on Thursday. The firm’s 50 day simple moving average is $5.80 and its 200 day simple moving average is $9.54. Enanta Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the transaction, the chief executive officer now owns 801,638 shares in the company, valued at approximately $6,461,202.28. This represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 13.89% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in Enanta Pharmaceuticals by 69.6% in the 4th quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company’s stock valued at $91,000 after buying an additional 6,518 shares during the last quarter. Trexquant Investment LP grew its stake in shares of Enanta Pharmaceuticals by 97.3% during the 4th quarter. Trexquant Investment LP now owns 135,954 shares of the biotechnology company’s stock worth $782,000 after acquiring an additional 67,040 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Enanta Pharmaceuticals by 47.6% during the 4th quarter. Wellington Management Group LLP now owns 51,298 shares of the biotechnology company’s stock worth $295,000 after acquiring an additional 16,547 shares in the last quarter. Norges Bank acquired a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $234,000. Finally, American Century Companies Inc. lifted its position in shares of Enanta Pharmaceuticals by 10.5% in the fourth quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 3,501 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.